Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588068 · ClinicalTrials.gov registry record
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
A clinical trial of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 2,070
- Enrollment target
- 1
- Study location
NCT00588068 is a study of Neuroblastoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2,070 participants, above the 217-participant average among 94 other Neuroblastoma trials with a reported enrollment target (854% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00588068, a study of Neuroblastoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 2,070 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Conditions Studied
Interventions
- OTHER Tumor and Marrow Markers
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,070 participants |
| Start Date | 2000-09-26 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588068
The ClinicalTrials.gov registry entry for NCT00588068 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,070 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 94 other Neuroblastoma trials with a reported enrollment target (854% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Tumor and Marrow Markers is the first listed.
NCT00588068 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00588068 about?
NCT00588068 is a clinical study titled "Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome". The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and t...
What is the current status of trial NCT00588068?
This trial is currently recruiting. The enrollment target is 2,070 participants. The study started on 2000-09-26. Estimated completion is 2026-09.
What conditions does trial NCT00588068 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00588068?
The interventions under investigation include: Tumor and Marrow Markers (OTHER).
Who is sponsoring clinical trial NCT00588068?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588068 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Neuroblastoma Biology Study
RECRUITING
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.